1577 related articles for article (PubMed ID: 12629332)
1. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
2. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
4. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
5. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA; Cerbón MA
Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
7. p53 mutations in bladder carcinoma cell lines.
Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
[TBL] [Abstract][Full Text] [Related]
8. Frequent association of p53 gene mutation in invasive bladder cancer.
Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of p53 gene mutations in bladder tumors.
Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
[TBL] [Abstract][Full Text] [Related]
10. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
11. Alterations of tumor suppressor genes in bladder cancer.
Cordon-Cardo C; Reuter VE
Semin Diagn Pathol; 1997 May; 14(2):123-32. PubMed ID: 9179973
[TBL] [Abstract][Full Text] [Related]
12. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
[TBL] [Abstract][Full Text] [Related]
13. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
14. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
Schlichtholz B; Presler M; Matuszewski M
Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
[TBL] [Abstract][Full Text] [Related]
16. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
17. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
18. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer.
Ozen H
Curr Opin Oncol; 1998 May; 10(3):273-8. PubMed ID: 9619365
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
